Alimera Sciences, Inc.

NasdaqGM:ALIM Stok Raporu

Piyasa değeri: US$301.3m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Alimera Sciences Yönetim

Yönetim kriter kontrolleri 1/4

Alimera Sciences' CEO is Rick Eiswirth, appointed in Jan 2019, has a tenure of 5.67 years. total yearly compensation is $3.26M, comprised of 18.5% salary and 81.5% bonuses, including company stock and options. directly owns 0.6% of the company’s shares, worth $1.80M. The average tenure of the management team and the board of directors is 2.1 years and 2.3 years respectively.

Anahtar bilgiler

Rick Eiswirth

İcra Kurulu Başkanı

US$3.3m

Toplam tazminat

CEO maaş yüzdesi18.5%
CEO görev süresi5.7yrs
CEO sahipliği0.6%
Yönetim ortalama görev süresi2.1yrs
Yönetim Kurulu ortalama görev süresi2.3yrs

Son yönetim güncellemeleri

Recent updates

Alimera Sciences: Deal Closing After All, CVR Still Attractive

Sep 11

Alimera Sciences: Cheap CVR Optionality

Jul 16

Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)

Jun 18
Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)

Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Feb 15
Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?

Dec 30
Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?

Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)

Oct 13
Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Sep 13
Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data

Oct 06

Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland

Sep 20

Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection

Aug 09

Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection

Jul 22

Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation

Jul 08

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Mar 24
Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?

Nov 06
Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?

Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Aug 24
Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares

Feb 11
Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares

Alimera Sciences (ALIM) Investor Presentation - Slideshow

Nov 18

CEO Tazminat Analizi

Rick Eiswirth'un ücretlendirmesi Alimera Sciences'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$15m

Mar 31 2024n/an/a

-US$23m

Dec 31 2023US$3mUS$603k

-US$21m

Sep 30 2023n/an/a

-US$21m

Jun 30 2023n/an/a

-US$25m

Mar 31 2023n/an/a

-US$17m

Dec 31 2022US$974kUS$580k

-US$18m

Sep 30 2022n/an/a

-US$18m

Jun 30 2022n/an/a

-US$17m

Mar 31 2022n/an/a

-US$7m

Dec 31 2021US$890kUS$550k

-US$4m

Sep 30 2021n/an/a

-US$1m

Jun 30 2021n/an/a

US$2m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$888kUS$550k

-US$5m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

-US$6m

Mar 31 2020n/an/a

-US$9m

Dec 31 2019US$977kUS$525k

-US$10m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

US$19m

Mar 31 2019n/an/a

US$22m

Dec 31 2018US$831kUS$495k

US$17m

Sep 30 2018n/an/a

US$11m

Jun 30 2018n/an/a

-US$22m

Mar 31 2018n/an/a

-US$23m

Dec 31 2017US$811kUS$425k

-US$22m

Tazminat ve Piyasa: Rick's total compensation ($USD3.26M) is above average for companies of similar size in the US market ($USD2.42M).

Tazminat ve Kazançlar: Rick's compensation has increased whilst the company is unprofitable.

CEO

Rick Eiswirth (56 yo)

5.7yrs

Görev süresi

US$3,261,480

Tazminat

Mr. Richard S. Eiswirth, Jr., also known as Rick, served as Interim Chief Financial Officer at Alimera Sciences, Inc. since 2022. He has been President of Alimera Sciences, Inc. since January 1, 2016 until...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Richard Eiswirth
CEO & Director5.7yrsUS$3.26m0.60%
$ 1.8m
Jason Werner
Chief Operating Officerless than a yearUS$1.39m0.0017%
$ 5.1k
Philip Ashman
President of International Operationsless than a yearUS$1.02m0.22%
$ 655.2k
David Holland
Co-Founder21.3yrsUS$541.72k0.35%
$ 1.0m
Elliot Maltz
CFO & Treasurerless than a yearVeri yok0%
$ 0
Christopher Visick
VP, General Counsel & Secretary5.8yrsVeri yokVeri yok
David Dyer
Chief Retina Specialist3.3yrsVeri yok0.0083%
$ 25.1k
Todd Wood
President of U.S. Operationsless than a yearVeri yok0%
$ 0

2.1yrs

Ortalama Görev Süresi

55.5yo

Ortalama Yaş

Deneyimli Yönetim: ALIM's management team is considered experienced (2.1 years average tenure).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Richard Eiswirth
CEO & Director5.7yrsUS$3.26m0.60%
$ 1.8m
Peter Pizzo
Independent Director14.4yrsUS$186.31k0.00092%
$ 2.8k
Margaret Pax
Directorless than a yearUS$96.42k0%
$ 0
Ross DeMont
Director1.7yrsUS$124.63k0%
$ 0
John Snisarenko
Independent Director5.2yrsUS$172.21k0.018%
$ 55.4k
Michael Kaseta
Independent Director1.5yrsUS$151.70k0%
$ 0
Adam Morgan
Chairman of the Board1.5yrsUS$165.75k0%
$ 0
Erin Parsons
Director2.8yrsUS$172.52k0%
$ 0

2.3yrs

Ortalama Görev Süresi

53.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ALIM's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.